Pharmaxis Ltd (ASX:PXS) has been granted a trading halt by the ASX pending the release of information regarding a share placement.
The company’s shares will remain halted until the earlier of, the release of relevant information, or, the commencement of trading next Tuesday.
READ: Pharmaxis powering ahead with phase I LOXL2 studies
Pharmaxis is an established pharmaceutical research company working on new therapies to treat inflammatory and fibrotic diseases.
This includes liver disease NASH, pulmonary fibrosis, kidney and liver fibrosis, inflammatory bowel diseases and cancer.
The company finished the June quarter with just over $31 million in cash.